… of products (drugs, devices), and there is a commercial application for this … AD drug
development, how translational neuroscience approaches may be applied to AD drug development, …

… on development of DMTs for individuals with early disease, … for continuing progress in the
AD drug development field, and to … for continuing development in the AD space beyond 2025. …

… cohort or of the disease mechanisms of an individual case… drug development from the
single-target strategy to a multi-target strategy can dramatically increase the chance of developing …

… drug development landscape for AD. By comparing preclinical and clinical drug development
… Targeting pathways involved in (neuro)inflammation remains a strategy of interest both in …

… The 2020 pipeline has innovations in clinical trials and treatment targets that provide hope
for greater success in AD drug development programs. Review of clinical trials over the past 5 …

… We discuss trial infrastructure changes that may accelerate clinical trials and drug
development. Our goal is to provide insight into the drug development process and to help drug …

… These hallmarks have become the main target of current drug development. In this review,
therapeutic approaches as well as clinical results, issues, perspectives, and main hypothesis …

… drugs, bottlenecks encountered in drug development, and the possible targets and therapeutic
strategies for future drug development. We … and methods for future drug therapies for AD. …

Alzheimer’s disease (AD) is a progressive neurodegenerative … in developing treatments for
neuropsychiatric indications in AD, including agitation, psychosis, apathy, and sleep disorders…

… in different phases of development (figure). In this Review, we provide an update-to-date
and comprehensive outline of the status of drug development for Alzheimer's disease, focusing …